← Back to Clinical Trials
Recruiting Phase 3 NCT06697886

A Study of the Efficacy and Safety of Antiwei Granules in the Treatment of Common Cold

Trial Parameters

Condition Common Cold
Sponsor Tasly Pharmaceutical Group Co., Ltd
Study Type INTERVENTIONAL
Phase Phase 3
Enrollment 480
Sex ALL
Min Age 18 Years
Max Age 65 Years
Start Date 2023-11-16
Completion 2025-06-25
Interventions
Antiwei GranulesAntiwei Granules Placebo

Brief Summary

To further evaluate the efficacy and safety of Antiwei granule in the treatment of common cold (wind-cold syndrome)

Eligibility Criteria

Inclusion Criteria: 1. It met the diagnostic criteria of common cold in western medicine; 2. In accordance with the TCM syndrome differentiation standard of wind-cold syndrome; 3. Male and female patients aged 18 to 65 years; 4. The disease duration at enrollment was ≤48 h; 5. At enrollment, 37.3 ° C ≤axillary temperature \< 38.5 ° C; 6. Informed consent was obtained voluntarily. Exclusion Criteria: 1. Complicated with influenza, pneumonia, suppurative tonsillitis, acute tracheobronchitis, acute pharyngeal conjunctivitis, acute viral or herpetic pharyngitis, acute viral or herpetic laryngitis; 2. Patients who had been infected with 2019-ncov in the past and still had symptoms such as cough and fatigue for nearly 3 months after the antigen turned negative; 3. Primary ciliary dyskinesia syndrome, other acute onset nasal diseases (such as allergic rhinitis, chronic rhinitis, acute and chronic sinusitis, etc.), previous nasal surgery or radiotherapy of the nasopharynx with nasal mucosal dy

Related Trials